Compare LOCL & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | MRKR |
|---|---|---|
| Founded | 2021 | 1999 |
| Country | United States | United States |
| Employees | 286 | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.2M | 22.5M |
| IPO Year | N/A | 2010 |
| Metric | LOCL | MRKR |
|---|---|---|
| Price | $1.09 | $1.22 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 13.9K | ★ 62.9K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.61 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $97.19 | N/A |
| Revenue Next Year | $33.69 | $936.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.98 | $0.81 |
| 52 Week High | $4.00 | $2.46 |
| Indicator | LOCL | MRKR |
|---|---|---|
| Relative Strength Index (RSI) | 28.72 | 36.50 |
| Support Level | $0.99 | $1.17 |
| Resistance Level | $1.22 | $1.54 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 7.35 | 5.70 |
Local Bounti Corp is a controlled environment agriculture company. The business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides. The products of the company include living lettuce, leafy greens, herbs, and others.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).